AstraZeneca

New data from the DESTINY-Breast01 Phase II trial reinforce the efficacy of Enhertu in HER2-positive metastatic breast cancer New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food and Drug Administration (FDA) approval of its Imfinzi (durvalumab) for an additional dosing option, a 1,500mg fixed dose every four … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 14-Aug-2020 — /EuropaWire/ — Global science-led biopharmaceutical company AstraZeneca (LSE/STO/NYSE: AZN) has announced it signed an agreement with the European Commission (EC) for the supply of up to 400 million doses of the AZD1222 COVID-19 vaccine. Building … Read the full press release →

ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years In pivotal ASCEND trial, 82% of patients with relapsed or refractory disease treated with Calquence remained progression … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 5-Jun-2020 — /EuropaWire/ — British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca announced it will present new data across continuum of care from its broad renal portfolio during the 57th virtual congress of the European Renal Association – … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the second-largest pharmaceutical company in Japan Daiichi Sankyo (Daiichi Sankyo Company, Limited), has just been granted Orphan Drug Designation (ODD) in … Read the full press release →

The company received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) Broad and equitable supply of the vaccine throughout the world at no profit during the pandemic First agreements for at least 400 … Read the full press release →

The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19 infection (PRESS RELEASE) CAMBRIDGE, 14-Apr-2020 — /EuropaWire/ — Pharmaceutical giant AstraZeneca to begin a randomised, global clinical trial to assess … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 26-Mar-2020 — /EuropaWire/ — Science-led biopharmaceutical group AstraZeneca (LSE/STO/NYSE: AZN) has announced that its Lokelma (sodium zirconium cyclosilicate) is now approved in Japan. It is used for the treatment of patients with hyperkalaemia (elevated levels of potassium … Read the full press release →

(PRESS RELEASE) BASEL, 6-Jan-2020 — /EuropaWire/ — ChemChina and Sinochem announce the creation of Syngenta Group. The new holding company is the consolidation of both companies’ agricultural assets. Mark Patrick, Chief Financial Officer (CFO) and member of the Syngenta Executive … Read the full press release →